Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
about
Tests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocolPD-L1 expression in human cancers and its association with clinical outcomesThe efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisClinical utility of nivolumab in the treatment of advanced melanomaNovel technologies and emerging biomarkers for personalized cancer immunotherapyClinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysisClinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-AnalysisImmunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigationsDevelopment of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerPredictive biomarkers in precision medicine and drug development against lung cancerThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunityTumor-infiltrating dendritic cells in cancer pathogenesisPeriodontitis: from microbial immune subversion to systemic inflammationPD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined SubgroupsPrognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeCombinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatinPD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.CtBP2 overexpression promotes tumor cell proliferation and invasion in gastric cancer and is associated with poor prognosis.A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomasCo-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinomaPrevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancerProgrammed death ligand-1 expression in non-small cell lung cancer.Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancerChronic thoracic spinal cord injury impairs CD8+ T-cell function by up-regulating programmed cell death-1 expression.Renal cell carcinoma: molecular biology and targeted therapyPD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomyPD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomasBlocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockadeCombination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivoClinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis
P2860
Q24186719-FF3E4FC4-7542-4B0E-A176-58357E53993CQ26738361-C2B19DFC-690B-406F-B82B-D2D376445B2EQ26740280-0433622D-2387-4508-864D-A95D54CFE892Q26751268-35CF5C8A-2960-4610-AEE4-D615F5D946B3Q26770780-0A362C24-1EC8-4910-82FA-B42F584453C4Q26775460-D92636AA-A36E-468E-BE19-703EFE41BE5AQ26778025-EB72DCFC-5011-4079-9ABB-1F4D1720FCA4Q26781038-F3BCF6C3-AB37-4143-B8DF-982E90822948Q26798047-142611A4-C9ED-4752-996F-F5E1E4CB990BQ26824536-9821D730-6921-4DF2-A543-FBB948D0DC5EQ26829847-A7B233AE-43D6-411B-A161-21AF39CD06DAQ26861633-81D10D3B-5F10-4701-908D-F5091AFC7528Q26996386-CFCF5301-A603-4C6C-B167-0CCA64AE26EFQ27853205-416F9699-5F3E-46A3-8C64-25E0CFC0FACDQ27853291-DD198B94-57C2-413C-B0A3-ACE837DDC41CQ28119095-9DBEB2C3-D1C4-4558-8A2B-F7ECA55FABE9Q28537820-58B4EB6C-849A-4A7D-9B99-21B874C1E314Q30275174-8D723EF5-E7C2-48FA-9E9B-92ECE37276AAQ33605673-25354D59-BFFA-499D-A35A-29BC52B2A534Q33709869-806BCBAD-5901-4623-A5FF-5CF0A1D8974AQ33710008-6CBD579F-CF41-4F2B-A010-B083BE341A78Q33808374-E78EDC11-0892-4DCE-8759-A4EFDBCAE393Q33889053-A159D875-4B76-4C22-B008-580FE4DD955DQ33915040-CD1B6B8C-41D6-4B2A-A7CE-1C1B5894DFBBQ34103836-9660623E-E076-4747-A73E-D7FC5EF2C9A4Q34265875-7A2EFA88-7C44-4BF8-9290-0C94E2537D8EQ34384255-82530B96-3212-4136-AAAB-F5D29AC9AD0EQ34406469-1B77900D-E849-4A9E-931F-0D93E32B7E2EQ34425775-D31D8C64-40D2-40BF-ADE6-99CDA8294D7FQ34459048-F9472199-2016-4C32-8F33-D968D2CD38A0Q34505107-EBD7D31B-295F-47C8-ADDF-B7C3CD8FA9A6Q34513914-FC9E9CD3-F362-44C9-B5A7-5E13E52B3AE9Q34544461-762F4B60-4B41-4C57-923E-FE67C00B420EQ34550012-6B6785A3-4667-4678-A60B-2D36A42C14C3Q35070603-F9BA0EB2-440F-44FD-A3B7-26B89867251AQ35089270-1BA22DFD-7F1F-424F-9686-FDF9B8F3C81FQ35182037-2AA651EC-D084-4750-8529-44AFDD82CD5EQ35184928-179051D5-67C2-48DE-81A1-0528067CE468Q35235365-665605BB-D00E-4099-870F-438171BD7BDDQ35290679-E1718EE9-66A2-4EBC-A976-B6A6ED993FE6
P2860
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antagonist antibodies to PD-1 ...... ment of advanced human cancer.
@en
type
label
Antagonist antibodies to PD-1 ...... ment of advanced human cancer.
@en
prefLabel
Antagonist antibodies to PD-1 ...... ment of advanced human cancer.
@en
P2860
P1476
Antagonist antibodies to PD-1 ...... ment of advanced human cancer.
@en
P2093
Lieping Chen
P2860
P304
P356
10.1158/1078-0432.CCR-12-2063
P407
P50
P577
2013-03-01T00:00:00Z